Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VIGL
FechaHoraFuenteTítuloSímboloCompañía
08/05/202406:40GlobeNewswire Inc.Vigil Neuroscience to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:VIGLVigil Neuroscience Inc
07/05/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
07/05/202415:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
07/05/202415:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
07/05/202415:05GlobeNewswire Inc.Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
17/04/202415:05GlobeNewswire Inc.Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
26/03/202406:05GlobeNewswire Inc.Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
20/03/202406:05GlobeNewswire Inc.Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
13/03/202406:05GlobeNewswire Inc.Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
12/03/202406:05GlobeNewswire Inc.Vigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VIGLVigil Neuroscience Inc
06/03/202415:25GlobeNewswire Inc.Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024NASDAQ:VIGLVigil Neuroscience Inc
29/02/202415:05GlobeNewswire Inc.Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024NASDAQ:VIGLVigil Neuroscience Inc
14/02/202410:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
07/02/202415:05GlobeNewswire Inc.Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:VIGLVigil Neuroscience Inc
03/01/202415:30GlobeNewswire Inc.Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesNASDAQ:VIGLVigil Neuroscience Inc
22/11/202315:05GlobeNewswire Inc.Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:VIGLVigil Neuroscience Inc
16/11/202315:05GlobeNewswire Inc.Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATENASDAQ:VIGLVigil Neuroscience Inc
07/11/202306:05GlobeNewswire Inc.Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
17/10/202306:05GlobeNewswire Inc.Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s DiseaseNASDAQ:VIGLVigil Neuroscience Inc
05/10/202315:01GlobeNewswire Inc.Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:VIGLVigil Neuroscience Inc
26/09/202306:05GlobeNewswire Inc.Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSPNASDAQ:VIGLVigil Neuroscience Inc
11/09/202311:00GlobeNewswire Inc.Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
08/09/202315:05GlobeNewswire Inc.Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist ProgramNASDAQ:VIGLVigil Neuroscience Inc
08/09/202306:05GlobeNewswire Inc.Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare ConferenceNASDAQ:VIGLVigil Neuroscience Inc
08/08/202306:05GlobeNewswire Inc.Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
07/08/202317:38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
07/08/202315:05GlobeNewswire Inc.Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
09/06/202315:15Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VIGLVigil Neuroscience Inc
08/06/202316:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VIGLVigil Neuroscience Inc
01/06/202306:00GlobeNewswire Inc.Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare ConferenceNASDAQ:VIGLVigil Neuroscience Inc
 Showing the most relevant articles for your search:NASDAQ:VIGL